Search

Chih-Cheng Lai,1 Cheng-Hsin Chen,2 Charlotte Yu Hsuan Lin,3 Cheng-Yi Wang,2 Ya-Hui Wang41Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; 2Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; 3Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA; 4Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, TaiwanBackground: This study aims to compare the effects of single inhaler triple therapy comprised of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs) with dual therapies comprised of either LABA/LAMA, ICS/LABA or separate ICS/LABA plus LAMA triple therapy.Methods: The Pubmed, Embase, and Cochrane databases were searched up to October 31st 2018. Only randomized controlled trials were included in the meta-analysis. The primary outcome was the rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations.Results: Seven studies fulfilling the inclusion criteria were included in the meta-analysis. Single inhaler triple therapy was associated with a significantly lower risk of COPD exacerbation compared with LABA/LAMA (rate ratio, 0.69; 95% confidence interval [CI] 0.55 to 0.87, I2=85%), and ICS/LABA (rate ratio, 0.81; 95% CI 0.73 to 0.89, I2=29%) dual therapy. Single inhaler triple therapy led to a more significant improvement in lung function and quality of life compared with LABA/LAMA and ICS/LABA dual therapy. Single inhaler triple therapy was associated with a higher risk of pneumonia compared with LABA/LAMA (risk ratio, 1.38, 95% CI 1.14 to 1.67, I2=0) dual therapy.Conclusions: The use of single inhaler triple therapy for COPD patients can result in lower rates of moderate or severe exacerbations of COPD as well as improved lung function and quality of life compared with dual therapy with LABA/LAMA or ICS/LABA.Keywords: COPD, triple therapy, randomized controlled trials, single inhaler

Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548. The authors advised that they have introduced errors while preparing this article which were oversighted by all authors.On page 1541, in Results section, Risk of moderate or severe COPD exacerbation; (rate ratio, 0.81; 95% CI, 0.73 to 0.89, I2=29%; Figure 1) should be (rate ratio, 0.80; 95% CI, 0.71 to 0.90, I2=37%; Figure 1); and in Secondary outcomes, (MD, −153; 95% CI, −2.23 to −0.84, I2=21%; Figure 3) should be (MD, −1.53; 95% CI, −2.23 to −0.84, I2=21%; Figure 3).Read the original article